Influence of apolipoprotein E alleles on post-angioplasty restenosis in woman;Influence des alleles de l'apolipoproteine E sur la restenose apres angioplastie coronaire chez la femme

Archives des Maladies du Coeur et des Vaisseaux

Volumn 91, Issue 12, 1998, Pages 1475-1479

  Flork, L ^a   Jouanel, P ^b   Lusson, J R ^a   Leaute, S ^b   Dauphin, C ^a   Motreff, P ^a   Justin, E Pierre ^a   Lamaison, D ^a   Boire, J Y ^c   Cassagnes, J ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; ARTICLE; CORONARY ARTERY OBSTRUCTION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPOPROTEINEMIA; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; RESTENOSIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETICS; GRAFT OCCLUSION; MIDDLE AGED;

ALLELES; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; APOLIPOPROTEINS E; FEMALE; GENE FREQUENCY; GRAFT OCCLUSION, VASCULAR; HUMANS; MIDDLE AGED;

EID: 0032254189     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hermans W, Rensing BJ, Strauss BH, Serruys PW. Prevention of restenosis after percutaneous transluminal coronary angioplasty : the search for a magic bullet. Am Heart J 1991 ; 122 : 171-87.
2. Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty : serial angiographic follow-up 229 patients. J Am Coll Cardiol 1988 ; 12 : 616-23
3. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, De Feyter PJ. Incidence of restenosis after successful coronary angioplasly : a time-related phenomenon : a quantitative angiographic study in 342 consecutive patients at 1, 2, 3 and 4 months. Circulation 1988 ; 77 : 361-71.
4. Utermann G, Jaeschke M, Menzel J. Familial hyperlipoproteinemia type III-Deficiency of a specific apolipoprotein (Apo E III) in very low density proteins. FEBS Lett 1975 ; 56 : 352-5.
5. Davignon J, Greeg RE, Sing CF. Apoliporotein E polymorphism and atherosclerosis. Arteriosclerosis 1988 ; 8 : 1-21.
6. Dallongeville J. Apolipoprotéine E : propriétés physiologiques, polymorphisme et atherosclérose. Sang Thromb Vaiss 1993 ; 5 : 707-17
7. Hixon J and the pathobiological determinants of the artrterosclerosis in youth (PDAY) research group. Apolipoprotein E polymorphisms affect atherosclerosis young males. Arteriosclerosis Thromb 1991 ; 11 : 1237-44.
8. Maca T, Ahmadi R, Derfler K et al. Elevated lipoprotein (a) and increased incidence of restenosis after femoropopliteal PTA. Rational for the higher risk of recurrence in females ? Atherosclerosis 1996 ; 127 : 27-34.
9. Bussière JL, De Bourayne J, Monsegu J et al. Le taux plasmatique de lipoprotéine (a) permet-il de prédire la resténose après angioplastie ? Arch Mal Coeur 1996 ; 89 : 425-9.
10. Van Bockxmeer FM, Mamotte CDS, Gibbons FA, Taylor RR. Apolipoprotein E4 homozygoty-a determinant of restenosis after coronary angioplasty. Atherosclerosis 1994 ; 110 : 195-202.
11. Van Bockxmeer FM, Mamotte CDS, Gibbons FA, Burke V, Taylor RR. Angiotensin-converting enzym and apolipoprotein E genotypes and restenosis after coronary angioplasty. Circulation 1995 ; 92 : 2066-71.
12. Damaraju S, Yu QT, Safavi F, Marain A. Apolipoprotein E4 is not a genetic risk factor for coronary artery disease or restenosis after precutaneous transluminal coronary angioplasty. Am J Cardiol 1995 ; 75 : 1181-3.
13. Barraud P, Albuisson E, Jouanel P et al. Lipoprotein(a) levels are related to the presence/absence of angiographic coronary artery disease : results from a cohort of 800 patients (abstract). J Am Coll Cardiol 1994 ; 1A-484A.
14. Trinder P. Determination of blood glucose using 4 aminophenazone. J Clin Pathol 1969 ; 22 : 246.
15. Allain CC, Poon LS, Chan CSG. Enzymatic determination of total serum cholesterol. Clin Chem 1974 ; 20 : 470-5.
16. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985 ; 37 : 268-85.
17. Robertson FW, Cumming AM. Effects of apolipoprotein E polymorphism on serum lipoprotein concentration. Arteriosclerosis 1985 ; 5 : 283-92.
18. Kamboh MI, Evans RW, Aston CE. Genetic effect of apolipoprotein (a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease. American black women. Atherosclerosis 1995 ; 117 : 73-81.
19. De Knijff P, Kaptein A, Boomsma D. Princes Frants RR, Havekeo LM. Apolipoprotein E polymorphism affects plasma levels of lipoprotein (a). Atherosclerosis 1987 ; 90 : 169-74.
20. Hofman A, Ott A, Breteler MMB et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997 ; 9046 : 151-4.
21. Poirier J, Davignon J, Bouthilier D, Kogan S, Bertrand P, Gauthier S. Apolipoptotein E polymorphism and Alzheimer's disease. Lancet 1993 ; 342 : 697-9.
22. Blain H, Merhed A, Visvikis S et al. Maladie d'Alzheimer : hypothèses impliquant les apolipoproteines E. Presse Med 1996 ; 25 : 763-8.
23. Pillot T, Goethals M, Vanloo B et al. Title specific modulation of the fusogenic properties of the Alzheimer beta-amyloid peptide by apolipoprotein E isoforms. Eur J Biochem 1997 ; 3 : 650-9.